Genus (GENSF) Change In Receivables: $-5.6 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENSF Genus PLC GENSF
71 GF Score
Price $31.07
GF Value $28.90
! 4 Warning Signs
View Full Analysis

What is Genus Change In Receivables?

Genus GENSF 71 Change In Receivables is $-5.6 Mil as of Jun. 2026. GuruFocus rates GENSF with a GF Score™ of 71/100 and a GF Value™ of $28.90. The stock has 4 warning signs investors should review.

Genus's change in receivables for the quarter that ended in Jun. 2026 was $3.7 Mil. It means Genus's Accounts Receivable declined by $3.7 Mil from Dec. 2025 to Jun. 2026 .

Genus's change in receivables for the fiscal year that ended in Jun. 2026 was $-5.6 Mil. It means Genus's Accounts Receivable increased by $5.6 Mil from Jun. 2025 to Jun. 2026 .

Genus's Accounts Receivable for the quarter that ended in Jun. 2026 was $113.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Genus's Days Sales Outstanding for the six months ended in Jun. 2026 was 48.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Genus's liquidation value for the six months ended in Jun. 2026 was $-136.3 Mil.

Genus  (OTCPK:GENSF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Genus's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=113.467/430*91
=48.16

2. In Ben Graham's calculation of liquidation value, Genus's accounts receivable are only considered to be worth 75% of book value:

Genus's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=58.267-335.467+0.75 * 113.467+0.5 * 111.6
=-136.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genus Change In Receivables Related Terms

Genus Change In Receivables Historical Data

* Premium members only.

The historical data trend for Genus's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genus Change In Receivables Chart

Genus Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.78 -11.74 -12.85 15.47 -5.60

Genus Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.49 5.18 9.91 -9.37 3.73
GENSF
71GF Score
Genus PLC GENSF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genus Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-5.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-5.6 Mil mean?
Genus (GENSF) has a Change In Receivables of $-5.6 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Genus and its competitors.
Is Genus' Change In Receivables too high?
Genus' current Change In Receivables is $-5.6 Mil. Overall, Genus has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Genus' Change In Receivables compare to VRTX and REGN?
Genus' Change In Receivables of $-5.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Genus and its competitors. Genus's current Change In Receivables is $-5.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Genus (GENSF) has a current Change In Receivables of $-5.6 Mil. The stock's GF Value™ is $28.90, compared to a current price of $31.07 — trading 7.5% above its estimated fair value. The current Change In Receivables is $-5.6 Mil. Genus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Genus (GENSF), the current Change In Receivables is $-5.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genus (GENSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genus stock appears to be overvalued. The current stock price of $31.07 is trading 7.5% above its estimated GF Value™ of $28.90.

Key valuation signals for GENSF:

  • Change In Receivables: $-5.6 Mil
  • GF Value™: $28.90 vs. price of $31.07 (7.5% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the GENSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genus Business Description

Address Matrix House, Basing View, Basingstoke, Hampshire, GBR, RG21 4FF
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
71GF Score

Get the complete analysis for GENSF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.07
Price
$28.90
GF Value